Washington University in St. Louis
- Country
- πΊπΈUnited States
- Ownership
- Private
- Established
- 1853-02-22
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.wustl.edu
Clinical Trials
12
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)β’ Click on a phase to view related trials
News
BostonGene's AI Model Identifies Five Novel Subtypes to Predict Immunotherapy Response in Kidney Cancer
BostonGene published a study in Cell Reports Medicine introducing the largest harmonized transcriptomic and clinical dataset in kidney cancer, analyzing over 3,600 patient samples.
WashU's Novel Nasal COVID-19 Vaccine Advances to U.S. Phase 1 Clinical Trials
FDA approves Ocugen's investigational new drug application for a nasal COVID-19 vaccine, developed at Washington University in St. Louis, advancing to Phase 1 clinical trials this spring.
Advanced Treatment Strategies Show Promise in Improving PTCL Patient Outcomes
Current PTCL patients face challenging 5-year survival rates of 25-35%, prompting researchers to explore personalized treatment approaches including histologic-based therapy and MRD testing.